Virtu Financial LLC decreased its position in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) by 29.5% during the first quarter, according to its most recent filing with the SEC. The firm owned 45,868 shares of the biotechnology company’s stock after selling 19,180 shares during the period. Virtu Financial LLC’s holdings in ZIOPHARM Oncology were worth $177,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of ZIOP. Amalgamated Bank bought a new position in shares of ZIOPHARM Oncology during the 4th quarter valued at $37,000. Allred Capital Management LLC purchased a new stake in shares of ZIOPHARM Oncology in the 4th quarter worth $40,000. SG Americas Securities LLC purchased a new stake in shares of ZIOPHARM Oncology in the 4th quarter worth $46,000. Legal & General Group Plc increased its stake in shares of ZIOPHARM Oncology by 30.6% in the 4th quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 6,054 shares in the last quarter. Finally, Gamble Jones Investment Counsel purchased a new stake in shares of ZIOPHARM Oncology in the 4th quarter worth $56,000. Hedge funds and other institutional investors own 35.20% of the company’s stock.
Shares of ZIOPHARM Oncology stock traded down $0.12 during trading on Wednesday, reaching $4.24. 682,665 shares of the stock traded hands, compared to its average volume of 1,601,726. The firm has a market cap of $688.13 million, a price-to-earnings ratio of -8.83 and a beta of 2.64. The company has a quick ratio of 8.89, a current ratio of 8.89 and a debt-to-equity ratio of 0.01. ZIOPHARM Oncology Inc. has a 52-week low of $1.56 and a 52-week high of $5.00.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. On average, equities analysts expect that ZIOPHARM Oncology Inc. will post -0.3 EPS for the current fiscal year.
Several equities research analysts have recently commented on ZIOP shares. Zacks Investment Research lowered ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and issued a $5.50 price target on shares of ZIOPHARM Oncology in a research note on Thursday, May 9th. Laidlaw assumed coverage on ZIOPHARM Oncology in a research note on Monday, April 1st. They issued a “buy” rating and a $7.50 price target for the company. BidaskClub upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. Finally, Lake Street Capital assumed coverage on ZIOPHARM Oncology in a research note on Thursday, April 4th. They issued a “buy” rating and a $7.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. ZIOPHARM Oncology has a consensus rating of “Buy” and an average target price of $5.75.
WARNING: This news story was first reported by Sundance Herald and is the property of of Sundance Herald. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://sundanceherald.com/2019/05/22/virtu-financial-llc-decreases-position-in-ziopharm-oncology-inc-ziop.html.
ZIOPHARM Oncology Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Article: What are different types of coverage ratios?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.